Corcept Therapeutics
CORT
190 hedge funds and large institutions have $1.61B invested in Corcept Therapeutics in 2017 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 75 increasing their positions, 50 reducing their positions, and 42 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 50
29% more call options, than puts
Call options by funds: $11.5M | Put options by funds: $8.91M
12.51% more ownership
Funds ownership: 65.37% → 77.88% (+13%)
12% more capital invested
Capital invested by funds: $1.43B → $1.61B (+$176M)
2% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 42
1% more funds holding
Funds holding: 189 → 190 (+1)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| 1 |
BlackRock
New York
|
+$66M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56.8M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$34.4M |
| 4 |
Renaissance Technologies
New York
|
+$23.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$16.8M |
Top Sellers
| 1 |
IA
Investor AB
Stockholm,
Sweden
|
-$14.5M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$8.86M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$5.51M |
| 4 |
Two Sigma Investments
New York
|
-$4.22M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$4.05M |
CORT Hedge Fund Activity: Q4 2017 in Review
190 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q4 2017, worth a combined $1.61B — up 12% from $1.43B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new CORT positions and 42 closed out — a net gain of 1 holder — while 75 added to existing stakes and 50 trimmed.
The largest buyer was BlackRock, adding an estimated $66M. The largest seller was Investor AB, exiting entirely with an estimated $14.5M sold.
- 190 institutional investors held Corcept Therapeutics (CORT) as of Q4 2017, up from 189 in Q3 2017.
- Funds reported $1.61B of Corcept Therapeutics stock for Q4 2017, up 12% quarter-over-quarter.
- 43 funds opened new Corcept Therapeutics positions in Q4 2017 and 42 closed out, a net change of +1 holder.
- The largest Corcept Therapeutics buyer in Q4 2017 was BlackRock, an estimated $66M added.
- The largest Corcept Therapeutics seller in Q4 2017 was Investor AB, an estimated $14.5M sold.
Based on aggregated 13F filings for Q4 2017.